BSG and prostate carcinoma: Although some studies showed mixed results, indicating variability in CD147 expression between different grades of prostate cancer depending on population studied [29, 38–42], some studies have reported that CD147 overexpression correlates with advanced tumor stages and higher grades, contributing to invasive behavior through increased MMP activity [43].